News

BC Platforms advances multiple sclerosis research

The data management company BC Platforms has announced collaborations with multiple partners to better understand the genetic basis of multiple sclerosis. BC Platforms also intends to build a research platform in Great Britain.

BC Platforms
Image Credit: BC Platforms

The Basel-based company will grant the biotechnology firm Biogen and the Accelerated Cure Project (ACP) access to its research platform and analysis tool, announced a statement.

By 2020, BC Platforms plans to create the world’s biggest platform for healthcare and industry, providing access to genomic and clinical data from more than five million people.

It has now launched the Open Biobank Research Enhancement Alliance (OBREA), whose members can use BC Platform’s platform.

The platform networks biobanks, researchers and industry members. The BC|RQUEST tool serves to better analyze the continuously growing amount of data.

Biogen and ACP are both members of OBREA and the collaboration will give both companies access to BC|RQUEST. Microsoft will provide the necessary cloud infrastructure.

“We are pleased that our data management and analytics platform is being used to better understand a disabling and unpredictable disease such as multiple sclerosis, the incidence of which has been increasing in recent years,” commented Tero Silvola, CEO of BC Platforms, in the statement.

BC Platforms has also entered into a partnership in Great Britain with the UK Clinical Research Collaboration Tissue Directory and Coordination Centre (UKCRC TDCC).

The partners plan to build a research platform for 150 biobanks, who work closely with the pharmaceutical sector.

Thanks to the platform that BC Platforms intends to build, biobanks could save time and money in finding suitable samples.

Recommend us

Related Content

Premium Partner

Strategic partners

Institutional partner

Official program